Dec. 4, 2024  – Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 million.

Nov. 18, 2024 — In November, Esperion presented  an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented at the 2024 American Heart Association Scientific Sessions, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcomes trial and a real-world analysis of bempedoic acid usage were presented at the conference.

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.

The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.

Nov. 21, 2024 — Royal Philips plans to unveil its next-generation 1.5T BlueSeal MR wide-bore scanner at RSNA 2024 in Chicago, Dec. 1-4. The latest generation scanner features a 70 cm wide-bore design and integrates AI-enabled MR Smart Workflow solutions, designed to enhance access and diagnostic confidence to improve outcomes for more patients. The MR Smart Workflow solutions increase daily patient throughput without compromising diagnostic quality to address the needs of high-demand healthcare environments.

Nov. 18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke. The new five-year findings demonstrate that Abbott's Amplatzer Amulet helps more patients avoid long-term use of blood-thinning medication compared to the Watchman device.

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).

Nov. 16, 2024  Anthos Therapeutics, Inc.recently presented new data at the American Heart Association (AHA) Scientific Sessions from its AZALEA-TIMI 71 study that demonstrated the novel factor XI inhibitor abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, as compared to rivaroxaban.

The deadline for early bird discounts for HIMSS25 is rapidly approaching.

Register by December 15 to save up to $500 on your pass for the HIMSS Global Health Conference & Exhibition.

HIMSS Global Health Conference & Exhibition will take place in Las Vegas, March 3-6, 2025.

For more information, please visit www.himssconference.com

 

Nov. 13, 2024 – A recent study has demonstrated the value of the single-exposure dual-energy X-ray detector in advancing cardiovascular risk assessment.

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. Procedures that previously required the use of two different devices can now be performed in a single procedure using a single device, simplifying workflows and procedures and potentially reducing the risk and improving outcomes for patients who might otherwise face multiple complex interventions. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now